- Home
- REXR vs LEGN Comparison
REXR vs LEGN Comparison
Compare REXR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REXR | LEGN |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 5.9B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | REXR | LEGN |
|---|---|---|
| Price | $41.24 | $22.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | $43.10 | ★ $69.67 |
| AVG Volume (30 Days) | 2.1M | ★ 2.5M |
| Earning Date | 10-15-2025 | 11-12-2025 |
| Dividend Yield | ★ 4.13% | N/A |
| EPS Growth | ★ 15.85 | N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | ★ $997,931,000.00 | $909,045,000.00 |
| Revenue This Year | $9.35 | $68.83 |
| Revenue Next Year | $3.81 | $51.27 |
| P/E Ratio | $29.23 | ★ N/A |
| Revenue Growth | 10.40 | ★ 74.75 |
| 52 Week Low | $29.68 | $22.28 |
| 52 Week High | $44.38 | $45.30 |
Technical Indicators
Market Signals| Indicator | REXR | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.97 | 21.96 |
| Support Level | $39.53 | $26.43 |
| Resistance Level | $41.71 | $28.97 |
| Average True Range (ATR) | 0.76 | 1.57 |
| MACD | 0.03 | -0.43 |
| Stochastic Oscillator | 67.52 | 0.91 |
Price Performance
Historical ComparisonAbout REXR Rexford Industrial Realty Inc.
Rexford Industrial Realty Inc is a real estate investment trust engaged in owning, operating, and acquiring industrial properties in Southern California infill markets. The goal is to generate attractive risk-adjusted returns for stockholders by providing superior access to industrial property investments in Southern California infill markets. It has one operating segment business of investing in, operating, and repositioning/redeveloping industrial real estate properties located in Southern California infill markets.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.